Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

AstraZeneca gets Chinese rights to Cubicin from Cubist

Executive Summary

AstraZeneca has licensed from Cubist Pharmaceuticals (anti-infective therapeutics) rights to develop and sell the lipopeptide antibiotic Cubicin (daptomycin for injection) in China and certain countries in the Middle East, Asia (excluding Japan), and Africa that are not already covered under existing license agreements.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies